Current Report Filing (8-k)
December 21 2018 - 4:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 17, 2018
DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-16133
|
|
06-1245881
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1633 Broadway, Suite 22C, New York, New York
(Address of principal executive offices)
10019
(Zip code)
(212) 489-2100
(Registrants telephone number, including area code)
None
(Former name or
former address, if changed since last report.)
Check the appropriate box below
if
the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2 below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under
the
Exchange
Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant
to Rule 14d-2(b) under
the Exchange
Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant
to Rule 13e-4(c) under
the Exchange
Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter)
or Rule 12b-2 of
the Securities Exchange Act of
1934 (§240.12b-2 of
this chapter).
☐
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.
|
Item 1.01 Entry into a Material Definitive Agreement
On December 17, 2018, Delcath Systems, Inc. (the Company) entered into a definitive licensing agreement for CHEMOSAT
®
commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg
area, Germany.
Under the terms of the seven-year agreement, Delcaths European subsidiary, Delcath Systems, Ltd. exclusively licenses medac to sell
and market CHEMOSAT in all member states of the European Union, Norway, Liechtenstein, Switzerland, and the United Kingdom. medac will pay Delcath 6,000,000 in a combination of upfront and success-based milestone payments. Additionally,
Delcath will receive a fixed transfer price per unit of CHEMOSAT as well as royalties. The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension.
Item 8.01 Other Information
As of the close of the trading day
on December 20, 2018, the Company had 9,082,852 shares of its Common Stock issued and outstanding.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
DELCATH SYSTEMS, INC.
|
|
|
|
Date: December 21, 2018
|
|
By:
|
|
/s/ Jennifer Simpson
|
|
|
Name:
|
|
Jennifer Simpson
|
|
|
Title:
|
|
President and Chief Executive Officer
|